Search company, investor...

Forty Seven


Acq - P2P | Acquired

Total Raised




About Forty Seven

Forty Seven is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by the immune system. This antibody is currently being evaluated in two Phase 1 clinical studies in patients with solid tumors and in patients with acute myeloid leukemia.

Headquarters Location

1490 O'Brien Drive Suite A

Menlo Park, California, 94025,

United States


Missing: Forty Seven's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Forty Seven's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Forty Seven

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Forty Seven in 1 CB Insights research brief, most recently on Mar 4, 2020.

Expert Collections containing Forty Seven

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Forty Seven is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Forty Seven Patents

Forty Seven has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Monoclonal antibodies, Immune system, Immunology, Proteins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Monoclonal antibodies, Immune system, Immunology, Proteins



Latest Forty Seven News

Forty Seven Players Quarantined After COVID-19 Cases On Australian Open Flights

Jan 16, 2021

Forty Seven Players Quarantined After COVID-19 Cases On Australian Open Flights Published MELBOURNE: Forty-seven players have been forced into two weeks of hotel quarantine in Melbourne after three coronavirus infections were reported on two chartered flights carrying them to the year’s first grand slam, the tournament organisers said on Saturday. Two dozen players who arrived from Los Angeles entered strict hotel quarantine after an aircrew member and Australian Open participant who is not a player tested positive for the new coronavirus. Later, another non-player passenger on a flight from Abu Dhabi tested positive, prompting the organisers to usher 23 players into hotel quarantine. All three who tested positive had been transferred to a health hotel, the organisers said in a statement. The players would not be able to leave their hotel rooms for 14 days and until they are medically cleared, they said. “They will not be eligible to practise.” The decision will translate into unequal preparation for the participants. Uruguayan Pablo Cuevas took to Twitter to express his feelings. “From having 5 hours of training in a bubble to this…(strict quarantine x 15 days). I will be showing you my workouts x Instagram (inside the room),” wrote the world number 68. Australia has agreed to accept about 1,200 players, officials and staff on 15 flights for the major sporting event that is due to begin next month. Apart from Cuevas, Mexican player Santiago Gonzalez also confirmed being on that flight in a social media post. Other players cited by local media as likely to be on the flight included Tennys Sandgren, who was granted special permission to travel from Los Angeles late last week after testing positive for the new coronavirus, which he had previously had, and world 13 doubles player Victoria Azarenka of Belarus. “We are communicating with everyone on this flight, and particularly the playing group whose conditions have now changed, to ensure their needs are being catered to as much as possible,” said tournament director Craig Tiley. Scottish former world number one Andy Murray revealed he tested positive for COVID-19 last week but said he was in good health and still hoped to compete. American Madison Keys pulled out last week after she tested positive. The inbound infections came as Australia recorded one locally acquired case, as states began to relax travel bans on signs an outbreak in the northern state of Queensland had been contained. NEW YORK: Robert Saleh has made history that extends far beyond any football field. The New York Jets’ new head coach has families and community leaders excited in neighborhoods all across the country, celebrating the first known Muslim American to hold that position in the NFL. That’s a source of great pride for a group that has been generally underrepresented in the league’s on-field leadership roles. Its something that shows the growing diversity of our nation, the inclusion were trying to achieve at all levels of our society, said Ibrahim Hooper, national communications director for the Council on American-Islamic Relations. And I think it’s a very positive sign. The 41-year-old Saleh, expected to be formally introduced next week by the Jets, is the son of Lebanese parents and grew up in the Detroit suburb of Dearborn, Michigan, which is home to the largest Muslim population in the United States per capita. I think hes just a trailblazer for a lot of coaches who are Muslim, to let them know that they do have a chance to be a head coach, said Lions offensive lineman Oday Aboushi, a practicing Muslim who has played in the NFL for eight seasons including his first two with the Jets. He shows them you do have a chance to be a defensive coordinator, you do have a chance to grow up and have a job at the professional level, Aboushi added. As long as youre professional and youre passionate about it like he is, I think a lot of people will look to him as a trailblazer, as far as everyone feeling like they could do it themselves and its an attainable dream. After Saleh’s college playing career as a tight end at Northern Michigan ended, he got his start in coaching by working as an assistant at Michigan State, Central Michigan and Georgia before being hired as a defensive intern by the Houston Texans in 2005. Then came stints with Seattle and Jacksonville before Saleh became San Franciscos defensive coordinator in 2017, helping the 49ers reach the Super Bowl last year with his No. 2-ranked unit. He was a popular candidate among the seven teams looking for a new coach this offseason, and quickly emerged as the favorite for the Jets job. Saleh, known for his energy on the sideline and being well-liked by players, impressed the Jets during his first remote interview. He was flown in a few days later for an in-person meeting with Jets chairman and CEO Christopher Johnson, president Hymie Elhai and general manager Joe Douglas at the team’s facility in Florham Park, New Jersey. After a two-day visit, Saleh left to meet with Philadelphia for its coaching vacancy but the Jets knew they found their new coach. The team announced Thursday night the sides reached an agreement in principle. As a pioneer in the sports world, Saleh will serve as an inspiration to many young American Muslims, Selaedin Maksut, the executive director of CAIR’s New Jersey chapter, said in email to The Associated Press. “In addition to the positive impact that hell have on Muslims, Salehs presence in the field and on the screen will remind the rest of America that Muslims are a part of the fabric of this nation and proudly contribute to society. Its a step toward tearing down walls and building bridges. Welcome to Jersey, brother! Ahmed Mohamed, the legal director of CAIR’s New York chapter, congratulated the Jets and Saleh for what he called a historic hiring in the National Football League. He’s optimistic it’s a sign of increasing inclusion and recognition of the Muslim community. For all the Muslim youth who may be told they dont belong or cant do something because of how they pray, we hope that when they see Mr. Saleh on national television, they will say to themselves that anything is possible and will reach for the stars,” Mohamed said in an email to the AP. “We hope Mr. Salehs hiring opens the door for other American Muslims in sports. Saleh is believed to be the third Arab American to become a head coach in the NFL. He follows Abe Gibron, who led Chicago from 1972-74, and Rich Kotite, who coached the Eagles (1991-94) and Jets (1995-96) both of whom also had Lebanese roots. Saleh is also just the fourth active NFL head coach who is a minority, joining Miami’s Brian Flores, Washington’s Ron Rivera and Pittsburgh’s Mike Tomlin. Robert Saleh has made history on the field and off, New York City Mayor Bill de Blasio tweeted Friday night. Now hes knocking down barriers in our own backyard. Congrats, Coach! While Saleh’s focus will be on restoring the Jets to respectability and not necessarily being an inspiration, he has provided a path for others to someday follow. Any person in a new job, their first goal is going to be performance in their job, Hooper said. “But I think a secondary consideration might be being an example to Muslim and Arab American youth around the country, that this kind of inclusion and respect for diversity is possible. But I dont think he got the job because of his ethnic or religious background. He got this job because hes good at what he does. ___

Forty Seven Frequently Asked Questions (FAQ)

  • Where is Forty Seven's headquarters?

    Forty Seven's headquarters is located at 1490 O'Brien Drive, Menlo Park.

  • What is Forty Seven's latest funding round?

    Forty Seven's latest funding round is Acq - P2P.

  • How much did Forty Seven raise?

    Forty Seven raised a total of $155M.

  • Who are the investors of Forty Seven?

    Investors of Forty Seven include Gilead Sciences, California Institute of Regenerative Medicine, Lightspeed Venture Partners, Google Ventures, Clarus and 5 more.

  • Who are Forty Seven's competitors?

    Competitors of Forty Seven include Epsilogen, OncoResponse, Immune-Onc Therapeutics, Fortis Therapeutics, Pionyr Immunotherapeutics and 10 more.

Compare Forty Seven to Competitors

OncoResponse Logo

OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to increase the success rate of these therapies across multiple cancer types.

ImmunoMet Therapeutics

ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop anti-tumor and immuno-oncology therapies.

Immune-Onc Therapeutics Logo
Immune-Onc Therapeutics

Immune-Onc Therapeutics is a privately held cancer immunotherapy company dedicated to the discovery and development of biologic treatments for cancer patients. The company aims to translate scientific insights in the tumor microenvironment and immune suppressive pathways to develop biotherapeutics.

Fortis Therapeutics

Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody-drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.

Pionyr Immunotherapeutics Logo
Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Macrophage Pharma Logo
Macrophage Pharma

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Company's technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body's natural immune system to fight cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.